Paper Search Console

Home Search Page Alphabetical List About Contact

Journal Title

Title of Journal: Breast Cancer Res Treat

Search In Journal Title:

Abbravation: Breast Cancer Research and Treatment

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1002/art.37908

Search In DOI:

ISSN

1573-7217

Search In ISSN:
Search In Title Of Papers:

Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage

Authors: Lu Chen, Hannah M. Linden, Benjamin O. Anderson, Christopher I. Li,

Publish Date: 2014/08/28
Volume: 147, Issue:3, Pages: 609-616
PDF Link

Abstract

Improvement in breast cancer survival has been observed in recent decades in the U.S., but it is unclear if similar survival gains are consistent across breast cancer subtypes, especially with regards to more advanced stages of the disease. Data were from 13 population-based cancer registries participating in the surveillance, epidemiology, and end results (SEER) program, consisting of women between 20 and 79 years of age diagnosed with invasive breast cancer between 1992 and 2008. 2-year (1992–2008) and 5-year (1992–2006) breast cancer cause-specific survival rates were calculated and stratified by estrogen receptor (ER)/progesterone receptor (PR) status, stage, and race. Annual percent changes in survival rates were assessed. From 1992 through 1998–1999, 5- and 2-year cause-specific survival rates significantly improved across ER+/PR+, ER−/PR−, and ER+/PR− subtypes, with an annual increase ranging from 0.5 to 1.0 % in the 5-year rates. From 1998–1999 to 2006, different patterns were observed by ER/PR subtypes with survival rates slightly improving for ER+/PR+, continuing to improve at a rate of 0.5 % per year for ER−/PR−, and dropping 0.3 % annually for ER+/PR−. No significant survival gains were experienced by patients with ER−/PR+ cancer during the study period. In terms of advanced diseases, greatest annual increases in survival rates were seen for patients with stage III–IV ER+/PR+ and ER−/PR− tumors but less progress was observed for advanced ER+/PR− breast cancers. Steady improvements in survival rates for breast cancer have been achieved over the past several decades. However, 5-year survival rates for stage IV disease remained dismally below 20 % for most ER/PR subtypes.This work was supported in part by NCI (N01-PC95001). The dataset used for this analysis was obtained from the Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1992-2008), NCI, Department of Cancer Control and Population Sciences, Surveillance Systems Branch, released April 2014, based on the November 2013 submission. The NCI and SEER program were not involved in the design and conduct of this study, in the analysis or interpretation of the data, or in the preparation and review of this article.


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Variability in hormone and growth factor receptor expression in primary versus recurrent
  2. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage
  3. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort
  4. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast
  5. Feature extraction via composite scoring and voting in breast cancer
  6. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha
  7. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer
  8. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer
  9. Diagnosis and management of primary breast sarcoma
  10. Recurrent read-through fusion transcripts in breast cancer
  11. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial
  12. Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis
  13. Impact of carpal tunnel syndrome surgery on women with breast cancer-related lymphedema
  14. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
  15. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
  16. Body weight and risk of breast cancer in BRCA1/2 mutation carriers
  17. Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients
  18. Patterns of nodal staging during breast conservation surgery in the medicare patient: will the ACOSOG Z0011 trial change the pattern of care?
  19. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial
  20. CYP1B1 and predisposition to breast cancer in Poland
  21. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized
  22. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers
  23. The effect of delays in treatment for breast cancer metastasis on survival
  24. Correlation of HER2
  25. TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling
  26. HER3
  27. Metformin and breast cancer risk: a meta-analysis and critical literature review
  28. XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37

Search Result:



Help video to use 'Paper Search Console'